Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Global diversity of policy, coverage, and demand of COVID-19 vaccines: a descriptive study.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Additional Information
- Source:
Publisher: BioMed Central Country of Publication: England NLM ID: 101190723 Publication Model: Electronic Cited Medium: Internet ISSN: 1741-7015 (Electronic) Linking ISSN: 17417015 NLM ISO Abbreviation: BMC Med Subsets: MEDLINE
- Publication Information:
Original Publication: [London] : BioMed Central, 2003-
- Subject Terms:
- Abstract:
Background: Hundreds of millions of doses of coronavirus disease 2019 (COVID-19) vaccines have been administered globally, but progress on vaccination varies considerably between countries. We aimed to provide an overall picture of COVID-19 vaccination campaigns, including policy, coverage, and demand of COVID-19 vaccines.
Methods: We conducted a descriptive study of vaccination policy and doses administered data obtained from multiple public sources as of 8 February 2022. We used these data to develop coverage indicators and explore associations of vaccine coverage with socioeconomic and healthcare-related factors. We estimated vaccine demand as numbers of doses required to complete vaccination of countries' target populations according to their national immunization program policies.
Results: Messenger RNA and adenovirus vectored vaccines were the most commonly used COVID-19 vaccines in high-income countries, while adenovirus vectored vaccines were the most widely used vaccines worldwide (180 countries). One hundred ninety-two countries have authorized vaccines for the general public, with 40.1% (77/192) targeting individuals over 12 years and 32.3% (62/192) targeting those ≥ 5 years. Forty-eight and 151 countries have started additional-dose and booster-dose vaccination programs, respectively. Globally, there have been 162.1 doses administered per 100 individuals in target populations, with marked inter-region and inter-country heterogeneity. Completed vaccination series coverage ranged from 0.1% to more than 95.0% of country target populations, and numbers of doses administered per 100 individuals in target populations ranged from 0.2 to 308.6. Doses administered per 100 individuals in whole populations correlated with healthcare access and quality index (R 2 = 0.59), socio-demographic index (R 2 = 0.52), and gross domestic product per capita (R 2 = 0.61). At least 6.4 billion doses will be required to complete interim vaccination programs-3.3 billion for primary immunization and 3.1 billion for additional/booster programs. Globally, 0.53 and 0.74 doses per individual in target populations are needed for primary immunization and additional/booster dose programs, respectively.
Conclusions: There is wide country-level disparity and inequity in COVID-19 vaccines rollout, suggesting large gaps in immunity, especially in low-income countries.
(© 2022. The Author(s).)
- References:
Lancet. 2016 Oct 8;388(10053):1603-1658. (PMID: 27733283)
Lancet Glob Health. 2020 Aug;8(8):e1003-e1017. (PMID: 32553130)
Nat Rev Drug Discov. 2020 May;19(5):305-306. (PMID: 32273591)
Nat Hum Behav. 2021 Jul;5(7):947-953. (PMID: 33972767)
Lancet. 2021 Oct 9;398(10308):1377-1380. (PMID: 34534516)
EClinicalMedicine. 2021 Nov;41:101174. (PMID: 34746725)
Vaccine. 2021 Aug 23;39(36):5116-5128. (PMID: 34340856)
Lancet Infect Dis. 2021 Jul;21(7):922-923. (PMID: 34174236)
Vaccines (Basel). 2021 Aug 13;9(8):. (PMID: 34452026)
Science. 2021 Feb 19;371(6531):. (PMID: 33323424)
Lancet. 2012 Jul 7;380(9836):37-43. (PMID: 22579043)
PLoS Med. 2010 May 04;7(5):e1000247. (PMID: 20454566)
Nat Med. 2021 Aug;27(8):1385-1394. (PMID: 34272499)
Int J Infect Dis. 2021 Dec;113:336-338. (PMID: 34653654)
Vaccine. 2018 Feb 8;36(7):921-931. (PMID: 29336923)
Nat Med. 2021 Feb;27(2):225-228. (PMID: 33082575)
Nature. 2021 Dec;600(7890):701-706. (PMID: 34673755)
BMJ. 2020 Dec 15;371:m4704. (PMID: 33323388)
Lancet. 2021 Oct 9;398(10308):1317-1343. (PMID: 34562388)
Nat Hum Behav. 2021 Aug;5(8):1009-1020. (PMID: 34158650)
N Engl J Med. 2014 Feb 27;370(9):847-59. (PMID: 24571757)
Science. 2021 Nov 12;374(6569):879-882. (PMID: 34618594)
BMC Med. 2014 Oct 23;12:188. (PMID: 25338506)
Nat Med. 2021 Nov;27(11):2025-2031. (PMID: 34526698)
Lancet. 2020 Sep 26;396(10255):898-908. (PMID: 32919524)
PLoS One. 2012;7(3):e33025. (PMID: 22412979)
Lancet. 2021 Mar 13;397(10278):1023-1034. (PMID: 33587887)
Am J Epidemiol. 2022 Sep 28;191(10):1792-1802. (PMID: 35475891)
Lancet. 2018 Jun 2;391(10136):2236-2271. (PMID: 29893224)
Lancet. 2021 Feb 13;397(10274):562-564. (PMID: 33516284)
MMWR Morb Mortal Wkly Rep. 2021 Jun 04;70(22):818-824. (PMID: 34081685)
Science. 2021 Oct 22;374(6566):423-431. (PMID: 34672751)
World Econ. 2022 Feb;45(2):468-522. (PMID: 34548749)
Nat Commun. 2021 Jan 4;12(1):63. (PMID: 33397909)
Front Immunol. 2021 Jun 14;12:558270. (PMID: 34194418)
Lancet Infect Dis. 2022 Mar;22(3):310-312. (PMID: 35101243)
N Engl J Med. 2020 Dec 31;383(27):2603-2615. (PMID: 33301246)
Lancet. 2020 Oct 17;396(10258):1204-1222. (PMID: 33069326)
N Engl J Med. 2021 Jan 7;384(1):80-82. (PMID: 33270381)
Cell Host Microbe. 2021 Nov 10;29(11):1611-1619.e5. (PMID: 34688376)
Vaccines (Basel). 2021 Aug 14;9(8):. (PMID: 34452030)
- Grant Information:
R01 AI135115 United States AI NIAID NIH HHS
- Contributed Indexing:
Keywords: COVID-19 vaccines; Global diversity; Vaccination policy; Vaccine coverage; Vaccine demand
- Accession Number:
0 (COVID-19 Vaccines)
- Publication Date:
Date Created: 20220404 Date Completed: 20220405 Latest Revision: 20240826
- Publication Date:
20250114
- Accession Number:
PMC8977121
- Accession Number:
10.1186/s12916-022-02333-0
- Accession Number:
35369871
No Comments.